Get the Stockscreener App
16.34
1.93%
0.31
Newamsterdam Pharma Company Nv stock is traded at $16.34, with a volume of 277.25K.
It is up +1.93% in the last 24 hours and down -29.99% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$16.03
Open:
$16.08
24h Volume:
277.25K
Relative Volume:
0.30
Market Cap:
$1.80B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-7.60
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
+9.66%
1M Performance:
-29.99%
6M Performance:
-14.14%
1Y Performance:
-18.50%
1-Day Range:
$16.00
$16.59
1-Week Range:
$14.62
$17.27
52-Week Range:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
16.34 | 1.80B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
Is NewAmsterdam Pharma Company NV (NASDAQ: NAMS) A Good Investment Now? - Stocksregister
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares By Investing.com - Investing.com Canada
NewAmsterdam Pharma adds Adele Gulfo to its Board By Investing.com - Investing.com South Africa
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares - Investing.com Australia
NewAmsterdam Pharma adds Adele Gulfo to its Board - Investing.com
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - GlobeNewswire
Blockbuster Drug Veteran Who Led $12B Pfizer Unit Joins NewAmsterdam Board Before Critical Launch - Stock Titan
Arrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Sei Investments Co. Sells 14,456 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Insider Monkey
KLP Kapitalforvaltning AS Purchases Shares of 6,000 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low – Here’s Why - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Average Price Target from Analysts - Defense World
Where are the Opportunities in (NAMSW) - news.stocktradersdaily.com
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Team: 133,000 Shares Granted to Strategic New Hires - Stock Titan
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - MarketScreener
American Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Teacher Retirement System of Texas Makes New $276,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
When (NAMS) Moves Investors should Listen - news.stocktradersdaily.com
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading Cardiovascular Drug Developer NewAmsterdam Sets Key Investor Presentation - Stock Titan
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 By Investing.com - Investing.com Australia
Newamsterdam Pharma director James Topper buys $25,520 in shares - Investing.com Australia
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank - Defense World
Newamsterdam pharma COO sells shares worth $376,000 By Investing.com - Investing.com Canada
Newamsterdam Pharma director James Topper buys $25,520 in shares By Investing.com - Investing.com South Africa
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 - Investing.com India
Newamsterdam pharma COO sells shares worth $376,000 - Investing.com India
Newamsterdam Pharma COO Kling sells $2.36 million in stock By Investing.com - Investing.com Australia
Newamsterdam Pharma COO Kling sells $2.36 million in stock - Investing.com
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts - Defense World
Financial Metrics Exploration: Understanding NewAmsterdam Pharma Company NV (NAMS) Through Ratios - The Dwinnex
9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH - Defense World
(NAMS) Trading Advice - news.stocktradersdaily.com
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News
Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com Australia
Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com Australia
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):